Ministry of Health, Lusaka, Zambia.
Trop Med Int Health. 2011 Jul;16(7):819-27. doi: 10.1111/j.1365-3156.2011.02777.x. Epub 2011 Apr 13.
Global eradication of tuberculosis (TB) depends on identification and treatment of all active TB cases and of the two billion people who are estimated to be latently infected with Mycobacterium tuberculosis. The past decade has seen a renaissance of scientific activities and funder investment into development of new TB drugs, diagnostics, biomarkers and vaccines. This viewpoint critically summarises the promising portfolio of more accurate TB diagnostics, new TB drugs and vaccines that have been endorsed by the STOP TB Partnership. Increasing numbers of Phase 2 and 3 drug, vaccine and diagnostic clinical trials in high-TB endemic areas reflect substantial progress towards attaining Global STOP-TB Partnership targets. Achievement of STOP-TB Partnership goals will crucially depend on political will and serious investment by funders and developing country governments into improving delivery of better health services and living conditions for their people. Long-term sustainability of any newer tools implemented at point of care is essential.
全球结核病（TB）的消除取决于对所有活动性结核病病例以及估计有 20 亿人潜伏感染结核分枝杆菌的人的发现和治疗。过去十年中，科学活动和资金投入在开发新的结核病药物、诊断工具、生物标志物和疫苗方面呈现出复兴的态势。本观点批判性地总结了更为准确的结核病诊断、新的结核病药物和疫苗的前景，这些已得到遏制结核病伙伴关系的认可。在高结核病流行地区，越来越多的 2 期和 3 期药物、疫苗和诊断临床试验反映了在实现全球遏制结核病伙伴关系目标方面取得的实质性进展。遏制结核病伙伴关系目标的实现将在很大程度上取决于资金提供者和发展中国家政府的政治意愿和认真投资，以改善其人民的卫生服务和生活条件。在护理点实施任何新工具的长期可持续性至关重要。
